Our partner is focused on developing innovative cancer immunotherapies, particularly targeting immune checkpoint pathways to enhance the body's immune response against tumors. Their approach aims to address unmet needs in oncology and improve patient outcomes through advanced, targeted treatments.
This executive leader played a critical role in shaping our partner's strategy, while interfacing with investors and partners. They cultivated the existing pipeline and maneuvered preclinical assets through the clinical process. They also managed an IND for the lead candidate (treatment of Acute Myeloid Leukemia -AML) in Q2 2020.
days until hired candidate presented
candidates presented
days until search completed